Acenda Pharma, Inc.

United States of America

Back to Profile

1-2 of 2 for Acenda Pharma, Inc. Sort by
Query
Aggregations
IPC Class
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids 1
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate 1
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin 1
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine 1
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings 1
See more
Found results for  patents

1.

PHENOTHIAZINE DERIVATIVES AND METHODS OF USE THEREOF

      
Application Number US2017051641
Publication Number 2018/075172
Status In Force
Filing Date 2017-09-14
Publication Date 2018-04-26
Owner ACENDA PHARMA, INC. (USA)
Inventor
  • Cheng, Haiyung
  • Lin, Chi-Feng
  • Shih, Jhen-Hua
  • Wu, Alexander C. H.

Abstract

The present disclosure relates to phenothiazine derivatives such as conjugates of phenothiazine compounds, as well as pharmaceutical compositions thereof. The present disclosure also relates to a method of making and the use of such compounds for treating cancer, e.g., a lung cancer, a colon cancer, breast cancer or pancreatic cancer.

IPC Classes  ?

  • A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
  • C07D 279/24 - [b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom

2.

METHOD AND IMPROVED PHARMACEUTICAL COMPOSITION FOR IMPROVING THE ABSORPTION OF AN ESTER PRODRUG

      
Application Number CN2011076256
Publication Number 2012/174731
Status In Force
Filing Date 2011-06-24
Publication Date 2012-12-27
Owner ACENDA PHARMA, INC. (USA)
Inventor Cheng, Haiyung

Abstract

The present invention relates to a method and an improved composition for improving the absorption of an ester prodrug in a subject. The method includes co-administering to the subject an effective amount of the ester prodrug or a pharmaceutical acceptable salt thereof, and a sufficient amount of adjuvant to impede a carboxylesterase-mediated hydrolysis of the ester prodrug in vivo, wherein the adjuvant is selected from the group consisting of triacetin, triethyl citrate and a combination of both. The present invention also relates to a method for impeding carboxylesterase-mediated hydrolysis of esters, including ester prodrugs.

IPC Classes  ?

  • A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
  • A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters